Liquid biopsy is a novel, non-invasive blood test that enables healthcare providers to discover a range of information about a tumor, such as early cancer detection, genetic alterations that lead to cancer development and therapy resistance, as well disease monitoring. It has the potential to revolutionize cancer care and management and identify new therapeutic avenues.
Our latest infographic describes the use of liquid biopsy, its clinical significance, and how it can be a game-changer for cancer diagnosis and therapy.
Topics covered in this infographic:
- What is liquid biopsy?
- The biocomponents that liquid biopsy can detect, focusing on ctDNA which has been in the spotlight for its clinical value
- What information the ctDNA can provide?
- The uses of liquid biopsy
- Recommendations from researchers and professional bodies about liquid biopsy
- How liquid biopsy compares to traditional tumor biopsy
- NeoThetis liquid biopsy genetic test for therapy selection
References
The infographic was compiled using information from the following sources:
Lone, Saife, N et al. “Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.” Molecular cancer vol. 21,1 79. 18 Mar. 2022, doi: 10.1186/s12943-022-01543-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932066/?report=reader.
Palmirotta, Raffaele et al. “Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology.” Therapeutic advances in medical oncology vol. 10 1758835918794630. 29 Aug. 2018, doi: 10.1177/1758835918794630. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116068/?report=reader.
Corcoran, Ryan, B. “Liquid biopsy versus tumor biopsy for clinical-trial recruitment.” Nature medicine 26, 1815–1816, 2020, https://www.nature.com/articles/s41591-020-01169-6#citeas.
Nikanjam, Mina et al. “Liquid biopsy: current technology and clinical applications.” Journal of hematology & oncology vol. 15,1 131. 12 Sep. 2022, doi: 10.1186/s13045-022–01351-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465933/?report=reader.
Di Sario, Gianna et al. “Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review”. Frontiers in genetics. 2023 Apr 3;14:1152470. doi: 10.3389/fgene.2023.1152470.
Pinzani, Pamela et al. “Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors” Clinical chemistry and laboratory medicine (CCLM), vol. 59, no. 7, 2021, pp. 1181-1200, 5. Feb. 2021, https://doi.org/10.1515/cclm-2020-1685.
Armakolas, A et al. Liquid Biopsies, Novel Approaches and Future Directions. Cancers. 2023; 15(5):1579. https://www.mdpi.com/2072-6694/15/5/1579.
Pascual, J et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of oncology : official journal of the European Society for Medical Oncology vol. 33,8 (2022): 750-768. doi:10.1016/j.annonc.2022.05.520. https://www.annalsofoncology.org/article/S0923-7534(22)01721-5/fulltext.
